|
17 Jun 2020 |
Armata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense (DoD) for Development of Bacteriophage Therapy to Treat S. aureus Bacteremia Infections
|
|
17 Jun 2020 |
CORAT Therapeutics Takes Over the Fast Track Development of a Novel COVID-19 Antibody Drug Program
|
|
17 Jun 2020 |
Sagimet Announces Positive Topline Results in 12-week NASH Phase 2 Clinical Trial of FASN Inhibitor TVB-2640
|
|
17 Jun 2020 |
ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial
|
|
17 Jun 2020 |
RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO
|
|
17 Jun 2020 |
Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics Including Lead Program Targeting IL-11 to Treat Fibrosis and Oncology
|
|
17 Jun 2020 |
Atara Biotherapeutics Announces First Patient Enrolled in Randomized Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of Multiple Sclerosis
|
|
17 Jun 2020 |
FDA Approves Second Biomarker-Based Indication for Merck’s KEYTRUDA® (pembrolizumab), Regardless of Tumor Type
|
|
17 Jun 2020 |
Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb
|
|
17 Jun 2020 |
Recordati: Isturisa® (osilodrostat) phase III LINC-4 trial meets its primary endpoint in Cushing’s disease
|
|
17 Jun 2020 |
FDA Approves First Treatment for Adult Onset Still’s Disease, a Severe and Rare Disease
|
|
17 Jun 2020 |
Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
|
|
17 Jun 2020 |
FDA approves gemtuzumab ozogamicin for CD33-positive AML in pediatric patients
|
|
17 Jun 2020 |
Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19
|
|
17 Jun 2020 |
Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
|
|
16 Jun 2020 |
Saiba AG Selects AGC Biologics to Develop and Produce COVID-19 Vaccine
|
|
16 Jun 2020 |
eTheRNA Raises EUR 34 Million in Series B Financing to Accelerate Multiple mRNA Therapeutic Development Programs Through to Clinical Proof of Concept
|
|
16 Jun 2020 |
Exicure Announces First Patient Dosed in Phase 2 Merkel Cell Carcinoma Trial of Cavrotolimod (AST-008)
|
|
16 Jun 2020 |
Immunomic Therapeutics Enters into License Agreement with Ichor Medical Systems to Use Electroporation (EP) Delivery Technology in Phase I Study of DNA Vaccine Therapy, ITI-1001
|
|
16 Jun 2020 |
C4 Therapeutics Raises $170 Million Financing to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-Concept and to Advance Proprietary Platform
|
